Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2024 Oct 18;19(10):e0312342. doi: 10.1371/journal.pone.0312342

Impulse control disorders and other non-motor symptoms in Sri Lankan patients with Parkinson’s disease

H M M T B Herath 1,*,#, K W S M Wijayawardhana 2,#, U I Wickramarachchi 3,#, Sunethra Senanayake 4,#, Chaturaka Rodrigo 5,#, Bimsara Senanayake 4,#
Editor: Maryam Bemanalizadeh6
PMCID: PMC11488724  PMID: 39423191

Abstract

The impact of non-motor symptoms is often overlooked in favour of the motor symptoms when managing Parkinson’s disease resulting in suboptimal patient outcomes. This study aimed to characterise the non-motor symptoms of Parkinson’s disease in a cohort of Sri Lankan patients with a special focus on the impulsive control disorders and other compulsive behaviours (ICDs-CB) that had not been previously studied in this population. All patients with idiopathic Parkinson’s disease followed up at the National Hospital of Colombo, Sri Lanka were included. The presence or absence of non-motor symptoms and their perceived impact was recorded with an interviewer administered questionnaire. Symptoms of anxiety and depression were assessed with Hamilton Anxiety and Depression scales. Presence of ICDs-CB was assessed with the questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease. Of 192 patients 97% (186) reported at least 2 non-motor symptoms. About 83% (160/192) screened positive for anxiety, 40% (76/192) for depression, and 17% (32/192) for an ICDs-CB. A lower Barthel index, history of past psychiatric disorders and family history of alcohol abuse were independent predictors of ICDs-DB. Managing both motor and non-motor symptoms are important to preserve the quality of life of patients with Parkinson’s disease. They should be screened for symptoms for anxiety and depression regularly during follow up and educated about the possibility of ICDs-CB soon after diagnosis.

Introduction

Parkinson’s disease (PD) is a neurodegenerative disorder that affects the motor and non-motor functions of the brain. In early PD research the focus was mainly on the motor symptoms, such as tremor, rigidity, and bradykinesia. However, with the advancement of neurobiology of disease and clinical observations, the non-motor aspects of PD are also gaining more attention [1]. Non-motor symptoms (NMS) comprise a range of neuropsychiatric, cognitive, sensory, sleep, and autonomic manifestations that can significantly impair the quality of life of PD patients [2]. Some NMS, such as depression, sleep disorders, and olfactory disturbances, can precede the onset of motor symptoms and may be overlooked or misdiagnosed [3]. Moreover, the progressive nature of PD may render some NMS more severe and disabling over time, but without being recognized or addressed by the caregivers or the physicians [4].

Impulsivity is a trait that involves rapid, unplanned responses to internal or external stimuli without regard for their negative consequences, and it is associated with many neuropsychiatric disorders including PD [5]. Impulse control disorders (ICDs) are characterized by the failure to resist an urge to perform an act that is harmful to oneself or others. In PD, ICDs can manifest as compulsive gambling, sexual behaviour, shopping, eating, or other behaviours (dopamine dysregulation syndrome /compulsive medication use, hobbyism, punding, and walkabout) [6,7]. Collectively these are called impulse control disorders and other compulsive behaviours (ICDs-CB). These behaviours are more frequent in PD patients than in the general population [8], and they have a significant impact on the psychosocial well-being of the patients and their caregivers. However, PD patients may not disclose such compulsive behaviours to their health care providers due to shame, denial, urge to continue the behaviour, or lack of awareness [4]. Therefore, clinicians should screen for ICDs-CB soon after the diagnosis of PD and educate patients and their caregivers about the potential risks and management strategies. The prevalence, types, and associations of ICDs in PD may vary across different countries and cultures [816] so it is important to have local data on ICDs-CB in PD.

Sri Lanka is a low-middle-income country with a population of 22 million and approximately 30 neurologists in the public health system where most of the population seeks treatment (1 neurologist per 730,000 people). Given the lack of a networked electronic medical record system, data on prevalence of PD is limited. Available data suggests an increase of PD burden in terms of age standardised mortality (8.2% increase), prevalence (20.5% increase) and disability adjusted life years lost (11.9% increase) in Sri Lanka between 1990 and 2016 [17]. Part of this increase may be due to more cases being diagnosed with the expansion of neurology services to rural parts of the country. Only a few studies have been conducted in Sri Lanka on detailed impact of PD and associated health problems (e.g., depression) on patient lifestyle [1820]. There are no previous publications on ICDs-CB from Sri Lanka and findings from other countries cannot be extrapolated to local patients as cultural and legal differences influence the self-reporting of compulsive behaviours.

The aim of this study was to characterise the non-motor symptoms (including depression and anxiety) in a cohort of Sri Lankan patients followed up for PD and estimate the prevalence of ICDs-CB by self-report. It also aimed to identify clinical and socio-demographic associations for self-reported ICDs-CB. ICDs-CB is studied within the broader context of other NMS because they collectively contribute to the overall burden of disease (e.g., anxiety or depression related to compulsive gambling).

Materials and methods

We conducted a descriptive cross-sectional study within the Institute of Neurology of the National Hospital of Sri Lanka in Colombo (NHSL), which is the largest public sector health care institution in Sri Lanka which provides multi-disciplinary care to PD patients [19]. The study was reviewed and approved before the study began by NHSL ethical committee and ethical clearance was taken from NHSL ethical committee (AAJ/ETH/COM/2021/November). Recruitment and Data collection was started on 1st of January 2022 and ended on 30th November 2023. Informed written consent was obtained from all participants prior to enrolment. STROBE guideline was used. We included all idiopathic PD patients followed up in NHSL according to the brain bank criteria [21]. We excluded patients who did not consent to participate in the study, patients with a diagnosis dementia, Parkinsonism plus, and those who had undergone brain surgery including deep brain stimulation. An interviewer-administered questionnaire was used to collect clinical and socio-demographic data from the patients in confidence. If needed, the assistance of a caregiver was sought with patient’s consent. There are three languages spoken in Sri Lanka (Sinhala, Tamil, and English) and patients were interviewed in their preferred language. We trained five medical officers by two consultant neurologists (HMMTB, BS) to fill the questionnaire and pre-tested its administration to minimise inter-observer variation. A full list of variables collected in this study and their definitions are available in S1 Table. Of note, the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease (QUIP) [22] was used to assess ICDs-CB, the Hamilton Scales for Anxiety (HAM-A) [23] and Depression (HAM-D) [24] were used to screen for anxiety and depression, and the Barthel index [25] was used to assess the activities of daily living. When recording details of pharmacological management, the levodopa equivalent daily doses (LEDDs) for dopamine agonists (DA) and for levodopa were calculated as described previously [26,27]. For this study, pramipexole, ropinirole, and rotigotine were considered as dopamine agonists, but no patients were on pramipexole or rotigotine. To capture the impact of both the drug dose and the duration of administration, a composite variable of dose*duration was created. When recording addictive substance use in medical history, history of smoking was defined as lifetime usage of at least 5 pack-years of cigarettes [28]. Personal or immediate family history (in parents, siblings, or children) of alcohol use disorder was assessed using DSM-V criteria [29]. To assess the self-perceived impact of NMS on the quality of life, patients were asked to rate how bothersome each of their NMS were, on a 10-point Likert scale.

The data were entered and analysed with SPSS (IBM, USA, version 25). Continuous variables were summarised according to measures of central tendency (mean, median) and measures of dispersion (standard deviation, inter-quartile range) according to normality of data distributions. Discrete data were summarised as counts and percentages. Summary statistics between different groups were compared using appropriate parametric (e.g., independent T test) and non-parametric tests for continuous variables, and with chi-square test for discrete variables in the unadjusted analysis. Independent associations for having anxiety, depression or an ICDs-CB were explored with either linear or logistic regression. All data are available with the authors and can be shared on request.

Results

A total of 192 consenting patients diagnosed with Parkinson’s disease were interviewed between 2022 September and 2023 September for this study. Of the total sample, 112 (58.3%) identified as males while the rest identified as females. The mean age was 64.09 years (SD: 8.69). Average age of onset of PD was 59.5 years (SD: 9.87) and the mean duration since diagnosis was 4.72 years (SD: 4.41). About 60% (117/192) of patients reported being employed prior to the diagnosis but only 13% (25/192) were employed at the time of the interview. The demographic characteristics of the participants are summarised in Table 1.

Table 1. Sociodemographic characteristics and relevant past medical history of the patient sample (Number = 192).

Characteristic Group Mean ± SD Number (%)
Gender Male 112 (58.3%)
Female 80 (41.7%)
Mean age 64.09 ± 8.69
Mean age of onset of PD 59.5 ± 9.87
Mean duration of PD 4.72 ± 4.41
Marital status Married 178 (92.7%)
Single 12 (6.3%)
Divorced 2 (1%)
Education level No schooling 12 (6.3%)
Primary education 29 (15.1%)
Secondary education 149 (77.6%)
Tertiary education 2 (1%)
Income* Below average 155 (80.7%)
Above average 37 (19.3%)
Employment before diagnosis Employed 117 (60.9%)
Unemployed 75 (39.1%)
Employment After diagnosis Employed 25 (13%)
Unemployed 167 (87%)
Financial dependents at home Yes 116 (60.4%)
No 76 (39.6%)
Availability of a caregiver at home Yes 161 (83.9%)
No 31 (16.1%)
Current/Past history of alcohol use disorder Yes 44 (22.9%)
No 148 (77.1%)
Family** history of alcohol use disorder Yes 41 (21.4%)
No 151 (78.6%)
Current or past history of smoking Yes 29 (15.1%0
No 163 (84.9%)
Family** history of smoking Yes 37 (19.3%)
No 155 (80.7%)
Current or past history substance abuse Yes 7 (3.6%)
No 185 (96.4%)
Family** history of substance abuse Yes 5 (2.6%)
No 187 (97.4%)
Past history of psychiatric disorders Depression 9 (4.7%)
Bipolar disorder 1 (0.5%)
Psychosis 9 (4.7%)
None 173 (90.1%)
Family** History of psychiatric disorders Depression 2 (1%)
Bipolar disorder 3 (1.6%)
Psychosis 9 (4.7%)
None 178 (92.7%)

*Average Income– 90100 Sri Lankan Rupees per month (450 United States dollars)

**Family–Parents, siblings and children.

(PD = Parkinson disease).

The most frequently reported NMS were fatigue, pain, and anxiety while psychosis, hallucination, and hyposmia were the least common (S2 Table). Regarding the self-perceived impact of each NMS, most patients indicated that fatigue and pain and / or unpleasant sensations as the most bothersome symptoms when scored on a 10-point Likert scale (S3 Table). Almost all (99.4%, 191/192) patients reported at least one NMS while 96.8% (186/192) reported at least two, and 9.3% (18/192) reported at least three symptoms.

Given that symptoms of anxiety and depression are important non-motor symptoms of PD, we queried into these symptoms in greater detail using HAM-A and the HAM-D scales (Table 2). Majority of patients screened positive for anxiety (160/192, 83.3%) while a significant proportion screened positive for depression (76/192, 40%). In the unadjusted analysis, an advanced PD stage (modified Hoehn and Yahr classification), a higher ropinirole dose*months, better education (>5 years of school education), being a smoker, presence of a caregiver, and a lower Barthel index were statistically significant associations for a higher HAM-A score (p<0.05). In the adjusted analysis (linear regression), only the modified Hoehn and Yahr stage, a higher ropinirole dose*months, and a lower Barthel index remained as independent significant predictors of a higher HAM-A score (Table 3). Similarly, a higher modified Hoehn and Yahr stage, better education, higher dose of ropinirole (in last 2 months), being a smoker, having a caregiver, and a lower Barthel index were significant associations (p<0.05) for a higher HAM-D score in the unadjusted analysis. In the adjusted analysis (linear regression) a lower Barthel index, higher modified Hoehn and Yahr stage, and a higher ropinirole dose remained as independent predictors of a higher HAM-D score (Table 4).

Table 2. Results of screening for anxiety and depression using the Hamilton anxiety (HAM-A) and depression (HAM-D) tools (N-192).

Anxiety level* Number (%) Depression severity* Number (%)
None 32 (16.6%) None 116 (60.4%)
Mild 153 (79.6%) Mild 44 (22.9%)
Mild to Moderate 3 (1.5%) Mild to Moderate 26 (13.5%)
Moderate to severe 3 (1.5%) Moderate to severe 5 (3%)
Severe 1 (0.5%) Severe 1 (0.5%)

*HAM A and HAM D = None = 0–7; mild = 8–14; Mild to Moderate = 15–23; Moderate to severe = 24–30; Severe >30.

Table 3. Independent significant predictors of a higher score in Hamilton anxiety (HAM-A) (anxiety screening).

Independent variable* Unstandardized Coefficients (B) p value 95% Confidence Interval
Lower Bound Upper Bound
Modified Hoehn and Yahr stage 0.823 <0.001 0.389 1.258
Ropinirol dose*months 0.044 <0.001 0.024 0.063
Lower Barthel index -0.057 0.001 -0.092 -0.022
Smoking (self) 1.431 0.155 -0.545 3.406
Presence of a caregiver 0.632 0.524 -1.324 2.589
Level of education 1.726 0.058 -0.062 3.513

*Independent variables with a p<0.05 in unadjusted analysis were selected for linear regression shown here. All variables assessed are given in S1 Table.

Table 4. Independent significant predictors of a higher score in Hamilton Depression (HAM-D) (depression screening).

Independent variable* Unstandardized Coefficients B p value 95.0% Confidence Interval for B
Lower Bound Upper Bound
Modified Hoehn and Yahr stage 1.14 <0.001 0.685 1.596
Lower Barthel index -0.066 <0.001 -0.102 -0.029
Smoking (self) 1.501 0.156 -0.58 3.583
Presence of a caregiver 0.122 0.907 -1.936 2.179
Level of education 1.645 0.084 -0.223 3.514
Dose of ropinirole for the last 2 months 1.389 0.045 0.034 2.743

*Independent variables with a p<0.05 in unadjusted analysis were selected for linear regression shown here. All variables assessed are given in S1 Table.

Regarding ICD-CBs, only one patient (0.5%) reported being aware of having a compulsive behaviour, while all the others had never been screened for or informed about ICDs-CB. According to QUIP results, 32 patients (16.7%, 32/192) screened positive for at least one ICDs-CB. The subcategories were as follows: compulsive gambling (1.6%, 3/192), compulsive sexual behaviour (1%, 2/192), compulsive buying (4.2%, 8/192), compulsive eating (8.3%, 16/192), hobbyism (6.3%, 12/192), punding (1%, 2/192), walkabout (10.9%, 21/192), compulsive medication use (0.5%,1/192). Among these 32 patients, 15 (46.9%) had two or more ICDs-CB (2 ICDs-CB: 4 patients; 3 ICDs-CB: 5 patients; 4 ICDs-CB: 5 patients; 5 ICDs-CB: 1 patient).

In unadjusted analysis, having a higher HAM-A or HAM-D score, having a lower Barthel index, having a history of alcohol abuse in family or self, being a smoker, and history of a past psychiatric illness were statistically significantly associated with having any ICDs-CB. All the variables that were assessed are listed in S1 Table. Of the significant associations, a lower Barthel index, history of a past psychiatric disorder and family history of alcohol abuse remained as independent predictors of having any ICDs-CB after adjusted analysis by logistic regression (Table 5). Both HAM-D and HAM-A scores were highly correlated with each other with a spearman correlation coefficient >0.7, and hence to avoid collinearity only one variable (HAM-D) was used in the logistic regression, and it was not an independent predictor of the outcome. Because the numbers for each ICDs-CB subtype were low, the analysis was not repeated by the subtype.

Table 5. Independent predictors for having any impulsive control disorders and other compulsive behaviours (logistic regression).

Independent variable P value Odds ratio 95% Confidence interval
Lower bound Upper bound
History of psychiatric illness 0.027 3.88 1.16 12.97
Family history of alcohol abuse <0.001 6.62 2.51 17.5
History of alcohol abuse 0.275 1.85 0.61 5.58
History of smoking 0.986 1.01 0.29 3.56
Barthel index score 0.007 0.97 0.96 0.99
HAM-D Score** 0.272 1.05 0.96 1.13

*Independent variables with a p<0.05 in unadjusted analysis were selected for logistic regression shown here. All variables assessed are given in S1 Table. **Hamilton Depression scale (HAM-D) and anxiety scale (HAM-A) scores were highly correlated and therefore HAM-D was used as a representative variable for both to avoid collinearity.

Discussion

This study, a first to assess NMS in PD including ICDs-CB in Sri Lankan patients, found that most patients had at least two NMS with fatigue and pain being the most bothersome. Symptoms of anxiety and depression were observed in over 80% and 40% of patients respectively. Almost all patients (except one) had never heard of ICDs-CB, though 16.7% of patients had symptoms of at least one ICDs-CB. The likelihood of having an ICDs-CB was higher in those with a lower Barthel index, a history of a psychiatric illness and a family history of alcohol abuse.

In our experience, healthcare workers in Sri Lanka mostly focus on motor symptoms of PD during medical consultations at the expense of NMS. Given the high patient to neurologist ratio, neurology units across the country are very busy with limited consultation time per patient which makes managing NMS and screening for anxiety or depression very difficult. It is interesting that fatigue and pain (plus unpleasant sensations) were identified by many patients as the most bothersome NMS. Literature also suggests that fatigue is one of the most frequent and disabling NMS reported in PD at the time of diagnosis (by one third of patients), and more patients report fatigue as the disease progresses [30]. Pain and/or unpleasant sensations is reported by up to 50% of patients with PD, more commonly described as lancinating, burning, or tingling sensations. These can be generalized sensations or those localized to specific parts of the anatomy such as the face, abdomen, genitals, and joints [31] .

Screening for anxiety and depression is another often neglected aspect of patient management in PD. Though a high proportion of patients screened positive for mild and moderate symptoms in this study, the prevalence of severe anxiety or depression was low (<4%). In a previous study published by us in 2016, the proportion of PD patients with symptoms of depression in the same institution was at a comparable 48% when assessed with HAM-D [19]. This is also consistent with global figures which places the prevalence of depression in PD to be between 30–40% [32]. However the proportion screening positive for anxiety symptoms was much higher than that reported in literature worldwide (20–50% of PD patients) [33]. Postural instability, gait dysfunction, experience of dyskinesias or on/off fluctuations, and young onset of disease are all known associations with anxiety in PD [34] and these were also probable contributors to anxiety in our patients since an advanced disease stage and less independence in activities of daily living were associated with higher HAM-A scores. It is noteworthy that demographic and socioeconomic factors such as marital status, employment and monthly income were correlated with both HAM-A and HAM-D scores but were not found to be significant, suggesting that these symptoms of anxiety and depression are mostly related to the direct impact of PD (and hence improve with better management of symptoms).

The most significant finding in this study is the first reported prevalence of Parkinson’s disease related ICDs-CB in Sri Lankan patients. The prevalence of ICDs in PD as reported in literature varies widely between countries (and across different studies within the same country) and a recently published systematic review found this range to be between 3.53% (in China) to 59% (in UK), worldwide [35]. In general, the prevalence of ICDs was higher in Europe and the Americas (20.8%) compared to Asia (12.8%) [35]. This may partly reflect the socio-cultural and legal system influences in Asian countries where gambling and sexual promiscuity are less tolerated as social vices. However, it may also reflect health system failures in low-middle-income countries due to inadequate consultation times, inability to access qualified healthcare workers, inadequate patient education, inability to access appropriate treatment once diagnosed or a combination of these factors. Interestingly when we compared our results with two studies from neighbouring India which reported a prevalence of ICDs to be 41% [36] and 43% [37], the observed prevalence in Sri Lanka was lower at 17%. The types of most frequently observed ICDs were also different in India with punding, compulsive medication use and hypersexuality predominating [36,37].

In our cohort, all patients except one had never heard of ICDs despite living with PD for years. Regarding the subtypes of ICDs-CB, compulsive eating, walkabout and compulsive buying were the most frequently reported behaviours in this study while compulsive gambling and sexual behaviours were rarely reported. The observed prevalence of these latter subtypes is higher in European countries such as Spain, Finland or in Asian countries like Japan where gambling and casual sex is legally and culturally more acceptable. Given the significant heterogeneity between studies (differences in study design, biases in data collection, different tools used to classify ICDs, less use of dopamine agonists in Asian countries, genetic differences across ethnicities) it is difficult to draw parallels and do head-to-head comparisons of data between countries. However, it stresses the importance of generating locally relevant data to guide clinical management of patients. For example, patients with PD may be at increased risk of sexually transmitted diseases or financial hardship due to ICD-CBs and this risk can be reduced if patients are screened and educated soon after a diagnosis of PD is made. The family members and caregivers when educated may be more understanding of these symptoms which will ultimately improve the quality of life of patients.

Previous studies have identified various risks for ICD-CBs in PD such as gender [14,36], formal education [9,10], race [38], age [9,10,12,16,39], age of onset of PD [37], marital status[9,10,37,38], smoking (family or self) [9,10,28,37,38], alcohol abuse (self or family) [9,10,39], history of gambling addiction in family [9,10], increased caffeine use [28], use of other substances of abuse including recreational drugs [38], personality traits [36,39,40], psychiatric disorders such as depression [38], duration and severity of PD (motor and non-motor symptoms) [9,10,16,28,37], duration and dose of prescribed drugs for PD (levodopa, dopamine agonists, monoamine oxidase inhibitors and amantadine) [915,37,41]. We assessed many of these factors in our study but only the Barthel index (reflection of PD severity), history of a psychiatric disorder and family history of alcohol abuse were independently associated with ICDs-CB. Association with Barthel index is probably reflective of severity of PD as none of the patients had another independent comorbidity affecting the activities of daily living. Despite a lot of patients screening positive for depression and anxiety, the HAM-A or HAM-D scores were not associated with having an ICDs-CB. However, having a past psychiatric diagnosis (confirmed in a psychiatry clinic according to ICD / DSM criteria) was an association reflecting the importance of a formal diagnosis by a trained professional (e.g., psychiatrist). A formal diagnosis is likely to be made after a detailed clinical assessment over multiple visits unlike using a screening tool on a single occasion as done in this study, which makes the latter observations less reliable and heavily influenced by current mood and other situational factors. Nevertheless, screening is still useful to triage PD patients for psychiatric referrals because as for neurology services, the psychiatric services are also limited in Sri Lanka.

There is a discrepancy of risk factors for ICD-CBs in PD as reported in this study and those that are reported in the literature. This discrepancy could be attributed to several reasons. Firstly, our sample size was relatively small, which may have limited the statistical power to detect significant associations. Secondly, cultural factors likely played a significant role in underreporting of ICD symptoms in our cohort. In Sri Lanka, behaviours such as compulsive gambling or hypersexuality carry a significant social stigma. As a result, patients may be reluctant to disclose such behaviours to healthcare providers, especially in a clinical setting where there is limited familiarity with these symptoms. Additionally, it is worth noting that the use of dopamine agonists—a key risk factor for the development of ICDs—was lower in our cohort compared to studies from Europe and North America. This is due to a combination of factors, including prescribing practices, cost constraints, and patient preference for levodopa-based treatments, which are more widely available and affordable in Sri Lanka. The lower exposure to dopamine agonists in our cohort may have reduced the overall prevalence of ICDs, thereby weakening the association between ICDs and known risk factors.

There are several limitations of this study. Firstly, it is a single centre study and hence findings are not generalisable to the whole country. Furthermore, NHSL is the largest tertiary level neurology service provider in the country and patients followed up in this hospital have more severe disease. Secondly, our period for building a rapport with patients was limited and hence the reported low prevalence of certain ICDs-CB such as compulsive gambling and sexual behaviours may be an underestimate. Thirdly all observations in this study were self-reported on a single occasion by patients or obtained after a limited clinical examination by the observer and hence affected by situational factors (mood, clinic waiting times, immediate financial problems) and time constraints. Such observations are less accurate than objective measurements (e.g., Barthel index measured by observing patient in their house) or repeated measurements (e.g., HAM-D measured at multiple clinic visits). Longitudinal studies, with repeated assessments over time, may provide a more accurate reflection. Fourthly we did not use validated questionnaires to measure all outcomes in this study. We specifically focused on anxiety and depression using validated scales because they are among the most common neuropsychiatric symptoms in PD and these two are also the most studied non motor symptoms in PD. However, a similar standard questionnaire like Non-Motor Symptoms Questionnaire (NMSQuest), or a quality of life (QoL) questionnaire was not used to assess the impact of NMS. Instead, patients were asked to rate how bothersome each of their NMS were on a 10-point Likert scale which is a subjective measurement with inter-participant bias. validated.We acknowledge that this could introduce some bias. Finally, lack of awareness of healthcare workers of ICDs-CB may also contribute to poor patient management but in this study, we did not interview healthcare workers to assess their knowledge on this aspect.

In conclusion, this study, a first in Sri Lanka focusing on NMS and ICDs-CB in Parkinson’s disease found that more than 85% of patients had at least two NMS. In addition, more than 80% and 40% of patients screened positive for anxiety and depression though most had mild symptoms only. Approximately 17% of the patients reported one or more ICDs-CB with compulsive eating, buying and walkabout being the most common. Almost all patients interviewed had not heard about ICDs-CB previously. It is recommended that clinicians specifically ask about NMS during follow up and come up with a management plan tailored to the patients’ needs. Symptoms of depression and anxiety should be screened for at least annually or whenever clinical history is suggestive and those with moderate or severe symptoms should be referred for a formal assessment. Every patient and their caregivers must be educated about ICDs-CB soon after diagnosis of PD. Education of healthcare workers via continuous medical education initiatives on ICDs-CB and mental health risks in PD is also needed to achieve these goals.

Supporting information

S1 Checklist. STROBE statement—checklist of items that should be included in reports of cross-sectional studies.

(DOC)

pone.0312342.s001.doc (91KB, doc)
S1 Table. Variables that were collected in this study and their definitions.

(DOCX)

pone.0312342.s002.docx (20.9KB, docx)
S2 Table. Frequency of non-motor symptoms reported by patients.

(DOCX)

pone.0312342.s003.docx (15.4KB, docx)
S3 Table. Self-perceived impact of each non-motor symptoms, scored on a 10-point Likert scale.

(DOCX)

pone.0312342.s004.docx (14.9KB, docx)

Acknowledgments

Daniel Weintraub, MD, Professor of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania and Shilpa H. Bhansali, PhD, Associate Director, Tech Licensing Penn Centre for Innovation, University of Pennsylvania for assisting to get the copyright agreement for QUIP questionnaire.

Abbreviations

ICDs-CB

Impulse Control Disorders and other Compulsive Behaviours

PD

Parkinson’s Disease

NMS

Non-Motor Symptoms

DSM-IV

Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition

DA

Dopamine Agonists

DA-LEDD

Levodopa Equivalent Daily Doses for Dopamine Agonists

L-dopa-LEDD

Levodopa Equivalent Daily Doses for Levodopa

QUIP

Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease

HAM-A

Hamilton Anxiety Scale

HAM-D

Hamilton Rating Scale for Depression

NHSL

National Hospital of Sri Lanka

DBS

Deep Brain Stimulation

BMI

Body Mass Index

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013. doi: 10.1038/nrdp.2017.13 [DOI] [PubMed] [Google Scholar]
  • 2.Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Movement Disorders. 2009;24(11):1641–9. doi: 10.1002/mds.22643 [DOI] [PubMed] [Google Scholar]
  • 3.Chaudhuri KR, Yates L, Martinez-Martin P. The non-motor symptom complex of Parkinson’s disease: a comprehensive assessment is essential. Curr Neurol Neurosci Rep. 2005;5(4):275–83. doi: 10.1007/s11910-005-0072-6 [DOI] [PubMed] [Google Scholar]
  • 4.Chaudhuri KR, Yates L, Martinez-Martin P. The non-motor symptom complex of Parkinson’s disease: A comprehensive assessment is essential. Current Neurology and Neuroscience Reports. 2005;5(4):275–83. doi: 10.1007/s11910-005-0072-6 [DOI] [PubMed] [Google Scholar]
  • 5.Moeller FG, Barratt ES, Dougherty DM, Schmitz JM, Swann AC. Psychiatric aspects of impulsivity. Am J Psychiatry. 2001;158(11):1783–93. doi: 10.1176/appi.ajp.158.11.1783 [DOI] [PubMed] [Google Scholar]
  • 6.Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol. 2007;64(8):1089–96. doi: 10.1001/archneur.64.8.1089 [DOI] [PubMed] [Google Scholar]
  • 7.Weintraub D, Mamikonyan E, Papay K, Shea JA, Xie SX, Siderowf A. Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease-Rating Scale. Mov Disord. 2012;27(2):242–7. doi: 10.1002/mds.24023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Kenangil G, Ozekmekci S, Sohtaoglu M, Erginoz E. Compulsive behaviors in patients with Parkinson’s disease. Neurologist. 2010;16(3):192–5. [DOI] [PubMed] [Google Scholar]
  • 9.Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63(7):969–73. doi: 10.1001/archneur.63.7.969 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589–95. doi: 10.1001/archneurol.2010.65 [DOI] [PubMed] [Google Scholar]
  • 11.Voon V, Hassan K, Zurowski M, de Souza M, Thomsen T, Fox S, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology. 2006;67(7):1254–7. doi: 10.1212/01.wnl.0000238503.20816.13 [DOI] [PubMed] [Google Scholar]
  • 12.Voon V, Hassan K, Zurowski M, Duff-Canning S, de Souza M, Fox S, et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology. 2006;66(11):1750–2. doi: 10.1212/01.wnl.0000218206.20920.4d [DOI] [PubMed] [Google Scholar]
  • 13.Fan W, Ding H, Ma J, Chan P. Impulse control disorders in Parkinson’s disease in a Chinese population. Neurosci Lett. 2009;465(1):6–9. doi: 10.1016/j.neulet.2009.06.074 [DOI] [PubMed] [Google Scholar]
  • 14.Giladi N, Weitzman N, Schreiber S, Shabtai H, Peretz C. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson’s disease: the role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol. 2007;21(5):501–6. doi: 10.1177/0269881106073109 [DOI] [PubMed] [Google Scholar]
  • 15.Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Brefel-Courbon C, et al. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol. 2012;35(6):261–5. doi: 10.1097/WNF.0b013e31826e6e6d [DOI] [PubMed] [Google Scholar]
  • 16.Ramirez Gomez CC, Serrano Duenas M, Bernal O, Araoz N, Saenz Farret M, Aldinio V, et al. A Multicenter Comparative Study of Impulse Control Disorder in Latin American Patients With Parkinson Disease. Clin Neuropharmacol. 2017;40(2):51–5. doi: 10.1097/WNF.0000000000000202 [DOI] [PubMed] [Google Scholar]
  • 17.Dorsey ER, Elbaz A, Nichols E, Abbasi N, Abd-Allah F, Abdelalim A, et al. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2018;17(11):939–53. doi: 10.1016/S1474-4422(18)30295-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Ketharanathan T, Hanwella R, Weerasundera R, de Silva VA. Major depressive disorder in Parkinson’s disease: a cross-sectional study from Sri Lanka. BMC Psychiatry. 2014;14(1). doi: 10.1186/s12888-014-0278-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Herath TB, Withana M, Rodrigo C, Gamage R, Gamage C. Prevalence and associations for symptoms of depression in patients with Parkinson’s disease: a Sri Lankan experience. International Journal of Mental Health Systems. 2016;10(1). doi: 10.1186/s13033-016-0079-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.De Silva R, Williams-Gray C, Barker RA, Muthukuda C, Amaratunga D, Sirisena D, et al. Associations Between Lifestyle Factors And Parkinson’s Disease In An Urban Sri Lankan Clinic Study. International Archives of Medicine. 2017;10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery & Psychiatry. 1992;55(3):181–4. doi: 10.1136/jnnp.55.3.181 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Weintraub D, Hoops S, Shea JA, Lyons KE, Pahwa R, Driver-Dunckley ED, et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson’s disease. Movement Disorders. 2009;24(10):1461–7. doi: 10.1002/mds.22571 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Maier W, Buller R, Philipp M, Heuser I. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. Journal of Affective Disorders. 1988;14(1):61–8. doi: 10.1016/0165-0327(88)90072-9 [DOI] [PubMed] [Google Scholar]
  • 24.Hamilton M. The Hamilton Rating Scale for Depression. Assessment of Depression1986. p. 143–52. [Google Scholar]
  • 25.Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. Md State Med J. 1965;14:61–5. [PubMed] [Google Scholar]
  • 26.Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67(1):58–63. doi: 10.1001/archneurol.2009.294 [DOI] [PubMed] [Google Scholar]
  • 27.Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25(15):2649–53. [DOI] [PubMed] [Google Scholar]
  • 28.Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ. Prospective cohort study of impulse control disorders in Parkinson’s disease. Mov Disord. 2013;28(3):327–33. doi: 10.1002/mds.25291 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.American Psychiatric A. Diagnostic and Statistical Manual of Mental Disorders 2013. [Google Scholar]
  • 30.Alves G, Wentzel-Larsen T, Larsen JP. Is fatigue an independent and persistent symptom in patients with Parkinson disease? Neurology. 2004;63(10):1908–11. doi: 10.1212/01.wnl.0000144277.06917.cc [DOI] [PubMed] [Google Scholar]
  • 31.Goetz CG, Tanner CM, Levy M, Wilson RS, Garron DC. Pain in Parkinson’s disease. Movement Disorders. 1986;1(1):45–9. doi: 10.1002/mds.870010106 [DOI] [PubMed] [Google Scholar]
  • 32.Aarsland D, Påhlhagen S, Ballard CG, Ehrt U, Svenningsson P. Depression in Parkinson disease—epidemiology, mechanisms and management. Nature Reviews Neurology. 2011;8(1):35–47. doi: 10.1038/nrneurol.2011.189 [DOI] [PubMed] [Google Scholar]
  • 33.Chen JJ, Marsh L. Anxiety in Parkinson’s disease: identification and management. Therapeutic Advances in Neurological Disorders. 2013;7(1):52–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Dissanayaka NNW, Sellbach A, Matheson S, O’Sullivan JD, Silburn PA, Byrne GJ, et al. Anxiety disorders in Parkinson’s disease: Prevalence and risk factors. Movement Disorders. 2010;25(7):838–45. doi: 10.1002/mds.22833 [DOI] [PubMed] [Google Scholar]
  • 35.Parra-Diaz P, Chico-Garcia JL, Beltran-Corbellini A, Rodriguez-Jorge F, Fernandez-Escandon CL, Alonso-Canovas A, et al. Does the Country Make a Difference in Impulse Control Disorders? A Systematic Review. Mov Disord Clin Pract. 2021;8(1):25–32. doi: 10.1002/mdc3.13128 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Paul BS, Singh G, Bansal N, Singh G, Paul G. Gender Differences in Impulse Control Disorders and Related Behaviors in Patients with Parkinson’s Disease and its Impact on Quality of Life. Ann Indian Acad Neurol. 2020;23(5):632–7. doi: 10.4103/aian.AIAN_47_20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Sharma A, Goyal V, Behari M, Srivastva A, Shukla G, Vibha D. Impulse control disorders and related behaviours (ICD-RBs) in Parkinson’s disease patients: Assessment using "Questionnaire for impulsive-compulsive disorders in Parkinson’s disease" (QUIP). Ann Indian Acad Neurol. 2015;18(1):49–59. doi: 10.4103/0972-2327.144311 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Petry NM, Stinson FS, Grant BF. Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2005;66(5):564–74. doi: 10.4088/jcp.v66n0504 [DOI] [PubMed] [Google Scholar]
  • 39.Voon V, Thomsen T, Miyasaki JM, de Souza M, Shafro A, Fox SH, et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol. 2007;64(2):212–6. doi: 10.1001/archneur.64.2.212 [DOI] [PubMed] [Google Scholar]
  • 40.Voon V, Sohr M, Lang AE, Potenza MN, Siderowf AD, Whetteckey J, et al. Impulse control disorders in Parkinson disease: a multicenter case—control study. Ann Neurol. 2011;69(6):986–96. doi: 10.1002/ana.22356 [DOI] [PubMed] [Google Scholar]
  • 41.Corvol JC, Artaud F, Cormier-Dequaire F, Rascol O, Durif F, Derkinderen P, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. 2018;91(3):e189–e201. doi: 10.1212/WNL.0000000000005816 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Vanessa Carels

10 Sep 2024

PONE-D-23-43579Impulse Control Disorders and other non-motor symptoms in Sri Lankan patients with Parkinson's DiseasePLOS ONE

Dear Dr. Herath,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 25 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Vanessa Carels

Staff Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.

The American Journal Experts (AJE) (https://www.aje.com/) is one such service that has extensive experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. Please note that having the manuscript copyedited by AJE or any other editing services does not guarantee selection for peer review or acceptance for publication.

Upon resubmission, please provide the following:

The name of the colleague or the details of the professional service that edited your manuscript

A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)

A clean copy of the edited manuscript (uploaded as the new *manuscript* file)”

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The reviewer would like to thank the authors for offering their work for reviewing.

While the authors have done an onerous task of studying, analyzing and writing, there are few observations noted which need to be addressed about the research in the reviewer’s opinion.

Their study on “Impulse control disorders and other non motor symptoms” is not only informative but interesting also.

1. Why the authors choose to study NMS and ICD together? If this is the first study to look for ICD why not alone to look for the incidence and risk factors for ICD.

Introduction:

It is nicely written.

Materials and Methods:

1. Strength is that they calculated the sample size. The sample size was calculated based on severe DHI. This score depends upon the type of dizziness vestibular has the least scored while phobic positional vertigo has maximum score. Is this a reason for small sample size?

Results

1. Most frequent reported in NMS are – Fatigue and pain were two most common. The authors have specifically looked for anxiety and depression using scales; kindly explain the same. Is the author bias regarding the occurrence of anxiety and depression in PD.

2. Which questionnaire used to capture NMS in PD.

3. There are strong association of disease factors with occurrence of ICD while in authors study there was no significant correlation. The reason need to be discussed in discussion

4. “This study, a first to assess NMS in PD including ICDs-CB in Sri Lankan patients, found that most patients had at least two NMS with fatigue and pain being the most bothersome” how does the authors conclude this as there was no quality of life correlation with the NMS.

Discussion

1. To strengthen the study, reference from one of the Indian study on ICD with gender variation and risk factors can also be added in the discussion.

Conclusion

1. “This study, a first in Sri Lanka focusing on NMS and ICDs-CB in Parkinson’s

344 disease found that more than 85% of patients had at least two NMS and that the symptoms of 345 fatigue and pain to have the most impact on their quality of life”- difficult to conclude this as no QOL score applied.

2. Spelling of Focusing need to be corrected in conclusion

Reviewer #2: The manuscript presents a study on the non-motor symptoms and impulse control disorders and other compulsive behaviours in Parkinson's disease patients in Sri Lanka. The technical soundness of the study is upheld by clear methodologies, detailed statistical analyses, and data that support the conclusions. However, on line 30, a revision of the sentence from "...that had not been previously in this population." to "...that had not been previously studied in this population" is recommended in order to improve clarity.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Birinder Singh Paul

Reviewer #2: Yes: Antonios Alexandros Demertzis

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 Oct 18;19(10):e0312342. doi: 10.1371/journal.pone.0312342.r002

Author response to Decision Letter 0


17 Sep 2024

Dear editor and the reviewers,

Thank you for your comments and evaluation of our manuscript which is much appreciated. We have addressed all your queries (in black) below and our response appears in red both in the manuscript and in the text below.

Reviewer #1: The reviewer would like to thank the authors for offering their work for reviewing.

While the authors have done an onerous task of studying, analyzing and writing, there are few observations noted which need to be addressed about the research in the reviewer’s opinion.

Their study on “Impulse control disorders and other non motor symptoms” is not only informative but interesting also.

1. Why the authors choose to study NMS and ICD together? If this is the first study to look for ICD why not alone to look for the incidence and risk factors for ICD.

We chose to study both non-motor symptoms (NMS) and impulse control disorders (ICDs) together because ICDs in Parkinson’s disease (PD) can be closely related to neuropsychiatric and non-motor symptoms of Parkinson disease and both collectively contribute to the overall disease burden (e.g. having NMS may be a risk factor for ICD, and vice versa). ICDs are often overlooked in clinical practice, and by assessing them alongside NMS, we aimed to capture a more comprehensive picture of the challenges faced by PD patients in Sri Lanka. We have added this to the introduction (Line 90 to 92) .

Introduction:

It is nicely written.

Thank you

Materials and Methods:

1. Strength is that they calculated the sample size. The sample size was calculated based on severe DHI. This score depends upon the type of dizziness vestibular has the least scored while phobic positional vertigo has maximum score. Is this a reason for small sample size?

We included all idiopathic PD patients followed up in NHSL who met the brain bank criteria (1) while excluding patients who did not consent, or patients with a diagnosis dementia, Parkinsonism plus, or those who had undergone brain surgery including deep brain stimulation to control signs and symptoms of Parkinsons disease. Under these criteria this is the maximum number of patients available to recruit.

Results

1. Most frequent reported in NMS are – Fatigue and pain were two most common. The authors have specifically looked for anxiety and depression using scales; kindly explain the same. Is the author bias regarding the occurrence of anxiety and depression in PD.

We specifically focused on anxiety and depression because they are among the most common neuropsychiatric symptoms in PD and can significantly impact patients' quality of life. Our use of the Hamilton Anxiety Rating Scale (HAM-A) and Hamilton Depression Rating Scale (HAM-D) was based on their wide acceptance in PD research as well as them being validated tools used by others in similar studies. These two are also the most studied non motor symptoms in PD and we have added 2 references of studies on depressive disorder in Parkinson’s disease in Sri Lanka.The focus on these symptoms is driven by clinical experience in our region, where such symptoms are often under-recognized and under-treated, hence contributing to patient morbidity. We acknowledge that this could introduce a bias, which we have acknowledged in the limitations section of the discussion (Line 363) .

2. Which questionnaire used to capture NMS in PD.

We were mostly concerned about the subjective perception of the impact of NMS on the patient and hence used a 10-point Likert scale to assess the self-perceived impact of NMS on the quality of life, patients were asked to rate how bothersome each of their NMS were. We did not observe them to record these objectively and did not use a standard tool like Non-Motor Symptoms Questionnaire (NMSQuest). This is acknowledged as a limitation. However, some specific aspects of MNS such as anxiety and depression were measured objectively with validated tools like the Hamilton Scales for Anxiety (HAM-A) and Depression (HAM-D). Similarly Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (QUIP) was used to assess ICDs-CB.

3. There are strong association of disease factors with occurrence of ICD while in authors study there was no significant correlation. The reason needs to be discussed in discussion

In our study a lower Barthel index, history of a past psychiatric disorder and family history of alcohol abuse remained as independent predictors of having any ICDs-CB after adjusted analysis by logistic regression. We agree that it is unexpected not to observe a significant correlation between disease factors, as these are described in the literature. This discrepancy could be attributed to several reasons. Firstly, our sample size was relatively small, which may have limited the statistical power to detect significant associations.

Secondly, cultural factors likely played a significant role in underreporting of ICD symptoms in our cohort. In Sri Lanka, behaviors such as compulsive gambling or hypersexuality carry a significant social stigma. As a result, patients may be reluctant to disclose such behaviors to healthcare providers, especially in a clinical setting where there is limited familiarity with these symptoms. In our experience, many patients and their caregivers had never heard of ICDs before their participation in the study. This lack of awareness may have resulted in the under-recognition of symptoms contributing to the lower observed prevalence of ICDs in our cohort compared to studies from other regions.

Additionally, it is worth noting that the use of dopamine agonists—a key risk factor for the development of ICDs—was lower in our cohort compared to studies from Europe and North America. This is due to a combination of factors, including prescribing practices, cost constraints, and patient preference for levodopa-based treatments, which are more widely available and affordable in Sri Lanka. The lower exposure to dopamine agonists in our cohort may have reduced the overall prevalence of ICDs, thereby weakening the association between ICDs and known risk factors.

Patients may minimize their symptoms during brief clinical encounters, especially when rapport with the healthcare provider is limited. Longitudinal studies, with repeated assessments over time, may provide a more accurate reflection of the relationship between disease factors and ICDs. In our revised discussion, we will elaborate on these potential limitations and suggest that future studies include larger sample sizes, more comprehensive screening, and longitudinal follow-up to better understand the risk factors for ICDs in PD patients in Sri Lanka.

Given the significant heterogeneity between studies (differences in study design, biases in data collection, different tools used to classify ICDs, less use of dopamine agonists in Asian countries, genetic differences across ethnicities) it is difficult to draw parallels and do head-to-head comparisons of data between countries. However, it stresses the importance of generating locally relevant data to guide clinical management of patients.

This information is now added to xx paragraph in discussion, Line 336-349

4. “This study, a first to assess NMS in PD including ICDs-CB in Sri Lankan patients, found that most patients had at least two NMS with fatigue and pain being the most bothersome” how does the authors conclude this as there was no quality-of-life correlation with the NMS.

This assessment is based on self-report by patients where on a likert scale of 10 the patients themselves graded how bothersome each symptom was. We now acknowledge on the limitations section that this reporting is subjective based on self-perception of patients and was not objectively verified by investigators using a validated quality of life assessment.

Discussion

1. To strengthen the study, reference from one of the Indian studies on ICD with gender variation and risk factors can also be added in the discussion.

We added the following 2 studies from India and added these to discussion.

“Interestingly when we compared our results with two studies from neighbouring India which reported a prevalence of ICDs to be 41% (2) and 43% (3), the observed prevalence in Sri Lanka was lower at 17%. The types of most frequently observed ICDs were also different in India with punding, compulsive medication use and hypersexuality predominating (2, 3)”

We also added these 2 studies in the discussion where we discuss risk factors for ICD.( line 281)

Conclusion

1. “This study, a first in Sri Lanka focusing on NMS and ICDs-CB in Parkinson’s

disease found that more than 85% of patients had at least two NMS”- difficult to conclude this as no QOL score applied.

Thank you for the suggestion. We have now deleted the reference to fatigue and pain here

2. Spelling of Focusing need to be corrected in conclusion

we will correct the spelling error in "focusing."

Reviewer #2: The manuscript presents a study on the non-motor symptoms and impulse control disorders and other compulsive behaviours in Parkinson's disease patients in Sri Lanka. The technical soundness of the study is upheld by clear methodologies, detailed statistical analyses, and data that support the conclusions. However, on line 30, a revision of the sentence from "...that had not been previously in this population." to "...that had not been previously studied in this population" is recommended in order to improve clarity.

Thank you for highlighting this. We will revise the sentence to improve clarity as suggested. The new sentence will read: "...that had not been previously studied in this population."

1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery & Psychiatry. 1992;55(3):181-4.

2. Paul BS, Singh G, Bansal N, Singh G, Paul G. Gender Differences in Impulse Control Disorders and Related Behaviors in Patients with Parkinson's Disease and its Impact on Quality of Life. Ann Indian Acad Neurol. 2020;23(5):632-7.

3. Sharma A, Goyal V, Behari M, Srivastva A, Shukla G, Vibha D. Impulse control disorders and related behaviours (ICD-RBs) in Parkinson's disease patients: Assessment using "Questionnaire for impulsive-compulsive disorders in Parkinson's disease" (QUIP). Ann Indian Acad Neurol. 2015;18(1):49-59.

Attachment

Submitted filename: Response to Reviewers.docx

pone.0312342.s005.docx (30.6KB, docx)

Decision Letter 1

Maryam Bemanalizadeh

7 Oct 2024

Impulse Control Disorders and other non-motor symptoms in Sri Lankan patients with Parkinson's Disease

PONE-D-23-43579R1

Dear Dr. Herath,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Maryam Bemanalizadeh

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thanks for the reviewing.

The authors have answered the queries raised in material and methods, discussion and conclusion.

We are satisfied will all their answers and response.

They have incorporated the changes in their manuscript.

Reviewer #2: The manuscript is well-written, the data support the conclusions and is compliant with ethical standards. Comments have been addressed.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Birinder Singh Paul

Reviewer #2: No

**********

Acceptance letter

Maryam Bemanalizadeh

10 Oct 2024

PONE-D-23-43579R1

PLOS ONE

Dear Dr. Herath,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Maryam Bemanalizadeh

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist. STROBE statement—checklist of items that should be included in reports of cross-sectional studies.

    (DOC)

    pone.0312342.s001.doc (91KB, doc)
    S1 Table. Variables that were collected in this study and their definitions.

    (DOCX)

    pone.0312342.s002.docx (20.9KB, docx)
    S2 Table. Frequency of non-motor symptoms reported by patients.

    (DOCX)

    pone.0312342.s003.docx (15.4KB, docx)
    S3 Table. Self-perceived impact of each non-motor symptoms, scored on a 10-point Likert scale.

    (DOCX)

    pone.0312342.s004.docx (14.9KB, docx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0312342.s005.docx (30.6KB, docx)

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES